{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260810931321/en/AbCellera-Announces-Positive-Top-Line-Phase-2-Clinical-Trial-Results-for-ABCL635-Demonstrating-Significant-Reduction-in-Frequency-and-Severity-of-Vasomotor-Symptoms-and-a-Favorable-Tolerability-Profile", "message": "News view counter 871849 successfully enlarged"}